Ont Health Technol Assess Ser. 2018 May 3;18(4):1-141. eCollection 2018.
The standard treatment option for medication-refractory essential tremor is invasive neurosurgery. A new, noninvasive alternative is magnetic resonance-guided focused ultrasound (MRgFUS) neurosurgery. We aimed to determine the effectiveness, safety, and cost-effectiveness of MRgFUS neurosurgery for the treatment of moderate to severe, medication-refractory essential tremor in Ontario. We also spoke with people with essential tremor to gain an understanding of their experiences and thoughts regarding treatment options, including MRgFUS neurosurgery.
We performed a systematic review of the clinical literature published up to April 11, 2017, that examined MRgFUS neurosurgery alone or compared with other interventions for the treatment of moderate to severe, medication-refractory essential tremor. We assessed the risk of bias of each study and the quality of the body of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We performed a systematic review of the economic literature and created Markov cohort models to assess the cost-effectiveness of MRgFUS neurosurgery compared with other treatment options, including no surgery. We also estimated the budget impact of publicly funding MRgFUS neurosurgery in Ontario for the next 5 years. To contextualize the potential value of MRgFUS neurosurgery as a treatment option for essential tremor, we spoke with people with essential tremor and their families.
Nine studies met our inclusion criteria for the clinical evidence review. In noncomparative studies, MRgFUS neurosurgery was found to significantly improve tremor severity and quality of life and to significantly reduce functional disability (GRADE: very low). It was also found to be significantly more effective than a sham procedure (GRADE: high). We found no significant difference in improvements in tremor severity, functional disability, or quality of life between MRgFUS neurosurgery and deep brain stimulation (GRADE: very low). We found no significant difference in improvement in tremor severity compared with radiofrequency thalamotomy (GRADE: low). MRgFUS neurosurgery has a favourable safety profile.We estimated that MRgFUS neurosurgery has a mean cost of $23,507 and a mean quality-adjusted survival of 3.69 quality-adjusted life-years (QALYs). We also estimated that the mean costs and QALYs of radiofrequency thalamotomy and deep brain stimulation are $14,978 and 3.61 QALYs, and $57,535 and 3.94 QALYs, respectively. For people ineligible for invasive neurosurgery, we estimated the incremental cost-effectiveness ratio (ICER) of MRgFUS neurosurgery compared with no surgery as $43,075 per QALY gained. In people eligible for invasive neurosurgery, the ICER of MRgFUS neurosurgery compared with radiofrequency thalamotomy is $109,795 per QALY gained; when deep brain stimulation is compared with MRgFUS neurosurgery, the ICER is $134,259 per QALY gained. Of note however, radiofrequency thalamotomy is performed very infrequently in Ontario. We also estimated that the budget impact of publicly funding MRgFUS neurosurgery in Ontario at the current case load (i.e., 48 cases/year) would be about $1 million per year for the next 5 years.People with essential tremor who had undergone MRgFUS neurosurgery reported positive experiences with the procedure. The tremor reduction they experienced improved their ability to perform activities of daily living and improved their quality of life.
MRgFUS neurosurgery is an effective and generally safe treatment option for moderate to severe, medication-refractory essential tremor. It provides a treatment option for people ineligible for invasive neurosurgery and offers a noninvasive option for all people considering neurosurgery.For people ineligible for invasive neurosurgery, MRgFUS neurosurgery is cost-effective compared with no surgery. In people eligible for invasive neurosurgery, MRgFUS neurosurgery may be one of several reasonable options. Publicly funding MRgFUS neurosurgery for the treatment of moderate to severe, medication-refractory essential tremor in Ontario at the current case load would have a net budget impact of about $1 million per year for the next 5 years.People with essential tremor who had undergone MRgFUS neurosurgery reported positive experiences. They liked that it was a noninvasive procedure and reported a substantial reduction in tremor that resulted in an improvement in their quality of life.
药物难治性特发性震颤的标准治疗方案是侵入性神经外科手术。一种新的非侵入性替代方法是磁共振引导聚焦超声(MRgFUS)神经外科手术。我们旨在确定MRgFUS神经外科手术治疗安大略省中重度、药物难治性特发性震颤的有效性、安全性和成本效益。我们还与特发性震颤患者进行了交流,以了解他们对包括MRgFUS神经外科手术在内的治疗方案的体验和想法。
我们对截至2017年4月11日发表的临床文献进行了系统综述,这些文献研究了单独使用MRgFUS神经外科手术或与其他干预措施比较治疗中重度、药物难治性特发性震颤的情况。我们根据推荐分级评估、制定和评价(GRADE)工作组标准评估了每项研究的偏倚风险和证据体质量。我们对经济文献进行了系统综述,并创建了马尔可夫队列模型,以评估MRgFUS神经外科手术与其他治疗方案(包括不手术)相比的成本效益。我们还估计了安大略省未来5年为MRgFUS神经外科手术提供公共资金的预算影响。为了将MRgFUS神经外科手术作为特发性震颤治疗方案的潜在价值置于背景中,我们与特发性震颤患者及其家人进行了交流。
九项研究符合我们临床证据综述的纳入标准。在非对比研究中,发现MRgFUS神经外科手术能显著改善震颤严重程度和生活质量,并显著降低功能残疾(GRADE:极低)。还发现它比假手术显著更有效(GRADE:高)。我们发现MRgFUS神经外科手术与深部脑刺激在震颤严重程度、功能残疾或生活质量改善方面无显著差异(GRADE:极低)。与射频丘脑切开术相比,我们发现震颤严重程度改善方面无显著差异(GRADE:低)。MRgFUS神经外科手术具有良好的安全性。我们估计MRgFUS神经外科手术的平均成本为23,507美元,平均质量调整生存期为3.69个质量调整生命年(QALY)。我们还估计射频丘脑切开术和深部脑刺激的平均成本和QALY分别为14,978美元和3.61 QALY,以及57,535美元和3.94 QALY。对于不符合侵入性神经外科手术条件的人,我们估计与不手术相比,MRgFUS神经外科手术的增量成本效益比(ICER)为每获得一个QALY 43,075美元。对于符合侵入性神经外科手术条件的人,与射频丘脑切开术相比,MRgFUS神经外科手术的ICER为每获得一个QALY 109,795美元;当深部脑刺激与MRgFUS神经外科手术比较时,ICER为每获得一个QALY 134,259美元。然而,值得注意的是,射频丘脑切开术在安大略省很少进行。我们还估计,按当前病例负荷(即每年48例)计算,安大略省为MRgFUS神经外科手术提供公共资金在未来5年的预算影响每年约为100万美元。接受MRgFUS神经外科手术的特发性震颤患者报告了该手术的积极体验。他们经历的震颤减轻改善了他们进行日常生活活动的能力并提高了生活质量。
MRgFUS神经外科手术是治疗中重度、药物难治性特发性震颤的一种有效且总体安全的治疗选择。它为不符合侵入性神经外科手术条件的人提供了一种治疗选择,并为所有考虑神经外科手术的人提供了一种非侵入性选择。对于不符合侵入性神经外科手术条件的人,与不手术相比,MRgFUS神经外科手术具有成本效益。对于符合侵入性神经外科手术条件的人,MRgFUS神经外科手术可能是几种合理选择之一。按当前病例负荷计算,安大略省为治疗中重度、药物难治性特发性震颤的MRgFUS神经外科手术提供公共资金在未来5年的净预算影响每年约为100万美元。接受MRgFUS神经外科手术的特发性震颤患者报告了积极体验。他们喜欢这是一种非侵入性手术,并报告震颤大幅减轻,从而提高了生活质量。